The facilitator in acute kidney injury: TWEAK;TWEAK, el facilitador del daño renal agudo

Nefrologia

Volumn 28, Issue 6, 2008, Pages 587-592

  Sanz, A B ^a   Sanchez Sanchez Nino M D ^a   Izquierdo, M C ^a   Moreno, J A ^a   Ucero, A C ^a   Benito Martin A ^a   Santamaria B ^a   Burgos, C ^a   Egido, J ^a,b   Ramos, A ^d   Berzal, S ^d   Coto, E ^b,c   Ruiz Ortega, M ^a   Blanco Colio, L M ^a   Ortiz, A ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Section of Nephrology   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; HUMAN; PHYSIOLOGY; REVIEW;

HUMANS; KIDNEY FAILURE, ACUTE; TUMOR NECROSIS FACTORS;

EID: 59049085876     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (78)

1. Ortiz A, Justo P, Sanz A, Lorz C, Egido J. Targeting apoptosis in acute tubular necrosis. Biochem Pharmacol 2003; 66: 1589-94.
2. Solez K, Morel-Maroger L, Sraer JD. The morphology of «acute tubular necrosis» in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58: 362-76.
3. Olsen TS, Olsen HS, Hansen HE. Tubular ultrastructure in acute renal failure in man: epithelial necrosis and regeneration. Virchows Arch A Pathol Anat Histopathol 1985; 406: 75-89.
4. Lorz C, Benito-Martín A, Justo P, Sanz AB, Sánchez Niño MD, Egido J, Ortiz A. Modulation of renal tubular cell survival: where is the evidence? Current Medicinal Chemistry 2006; 13: 763-771.
5. Winkles JA. The TWEAK-Fn14 cytokinereceptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; [Epub ahead of print].
6. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1-16. PMID: 17981048.
7. Sanz AB, Moreno JA, Sánchez-Nino MD, Ucero AC, Benito A, Santamaría B, Justo P, Izquierdo MC, Egido J, Blanco-Colio LM, Ortiz A. TWEAKing renal injury. Front Biosci 2008; 13: 580-589.
8. Chicheportiche Y, Bourdon PR, Xu H, Hsu Y, Scott H, Hession C, Garci I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272: 32401-32410.
9. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TWEAKR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14: 241-249.
10. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004; 9: 2273-2284.
11. Baxter FO, Came PJ, Abell K, Kedjouar B, Huth M, Rajewsky K, Pasparakis M, Watson CJ. IKK beta/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 2006; 133: 3385-3394.
12. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashekenazi A. Identification of a ligand for the death-domain containing receptor Apo3. Curr Biol 1998; 8: 525-8.
13. Wiley SR, Cassiano L, Lofton T, Davis Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-846.
14. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA. The mitogeninducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-33176.
15. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TWEAKR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14: 241-249.
16. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, Peifley KA, Winkles JA. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156: 1253-1261.
17. Brown SAN, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 2006; 397: 297-304.
18. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmatic tail binds tumour-necrosis-factorreceptor- associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappa B activation. Biochem J 2003; 371: 395-403.
19. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCLXL/ BCL-W expression. J Biol Chem 2005; 280: 3483-3492.
20. Winkles JA, Tran NL, Berens ME. TWEAK and Fn14: New molecular targets for cancer therapy? Cancer Lett 2005; 235: 11- 17.
21. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003; 278: 36005-36012.
22. Polek TC, Talpaz M, Darnay BG, Spivak- Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TWEAKR. Evidence for a second TWEAK receptor. J Biol Chem 2003; 278: 32317-32323.
23. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R: A previously unrecognised protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007; 178: 8183- 94. PMID: 17548657.
24. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006; 281: 13946-13971.
25. Zheng TS, Burkly LC. No End In Site: TWEAK/Fn14 Activation and Autoimmunity Associated End-Organ Pathologies. J Leukocyte Biology 2008 (in press).
26. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1998; 8: 525-528.
27. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, Daver JM. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002; 4: 126-33.
28. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 916-922.
29. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucrat J. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002; 133: 116-123.
30. Tanabe K, Bonilla I, Winkles JA, Strittmatter SM. Fibroblast growth factor-inducible- 14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 2003; 23: 9675-9686.
31. Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006; 70: 1750-1758
32. Sanz AB, Justo P, Sánchez-Niño MD, Blanco-Colio LM, Winkles JA, Kreztler M, Jakubowski A, Egido J, Ruiz-Ortega M, Ortiz A. The Cytokine TWEAK Modulates Renal Tubulointerstitial Inflammation. J Am Soc Nephrol 2008; 19: 695-703.
33. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/ Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179: 7949-7958.
34. Kaplan JM, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169: 6020- 6029.
35. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192: 1373-1380.
36. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, Zheng T, Schiffer L, Michaelson JS, Putterman C. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006; 176: 1889-1898.
37. Winkles JA, Tran NL, Brown SA, Stains N, Cunliffe HE, Berens ME. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007; 12: 2761-2771.
38. Blanco-Colio M, Martín-Ventura JL, Muñoz-García B, Moreno JA, Meilhac O, Ortiz A, Egido J. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci 2007; 12: 3648-3655.
39. Donohue PJ, Richards CM, Brown SAN, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23: 594-600.
40. Lynch CN, Wang YC, Lund JK, Chen Y, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455-8459.
41. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002; 299: 488-493.
42. Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, Hsu YM, Burkly LC. TWEAK induces mammary epithelial branching morphogenesis. Oncogene 2005; 24: 2613-2624.
43. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baetscher M, Wang B, Bissell DM, Burkly LC. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005; 115: 2330-2340.
44. Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu Y, Ambrose C, Zheng TS, Burkly LC. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002; 115: 267-274.
45. Jin L, Nakao A, Nakayama M, Yamaguchi N, Kojima Y, Nakano N, Tsuboi R, Okumura K, Yagita H, Ogawa H. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004; 122: 1175-1179.
46. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, Hoelzinger DB, Beaudry C, Coons SW, Berens ME. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003; 162: 1313- 1321.
47. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H. Multiple pathways of TWEAK-induced cell death. J Immunol 2002; 168: 734-743.
48. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, Maurer MH, Rossner M, Schneider A, Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004; 24: 8237-8244.
49. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, Tschopp J, Wajant H. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29: 1785-1792.
50. Wilson CA, Browning JL. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ 2002; 9: 1321-1333.
51. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003; 170: 341-348.
52. Felli N, Pedini F, Zeuner A, Petrucci E, Testa U, Conticello C, Biffoni M, Di Cataldo A, Winkles JA, Peschle C, De Maria R. Multiple members of the TNF superfamily contribute to IFN-gammamediated inhibition of erythropoiesis. J Inmunol 2005; 1: 1464-1472.
53. Dogra C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of myoD protein. J Biol Chem 2006; 281: 10327-10336.
54. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177: 2610-2620.
55. Xu H, Okamoto A, Ichikawa J, Ando T, Tasaka K, Masuyama K, Ogawa H, Yagita H, Okumura K, Nakao A. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GMCSF. Biochem Biophys Res Commun 2004; 318: 422-427.
56. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase- 9 in macrophages. Circ J 2004; 68: 396-399.
57. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 2000; 32: 102-7.
58. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, Murata K, Nakano T. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 2004; 318: 726- 733.
59. Ho DH, Vu H, Brown SAN, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004; 64: 8968-8972.
60. Polavarapu R, Gongora MC, Winkles JA, Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappaB pathway activation. J Neurosci 2005; 25: 10094-10100.
61. Gómez-Chiarri M, Ortiz A, Seron D, Glez E, Egido J. The intercrine superfamily and renal disease. Kidney Int 1993; Supl. 39: S81-S85.
62. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004; 382 (Pt 2): 393- 409.
63. Sanz AB, Santamaría B, Ruiz Ortega M, Egido J, Ortiz A. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2007; Aceptado.
64. Lorz C, Justo P, Sanz A, Subirá D, Egido J, Ortiz A. Paracetamol nephrotoxicity: a role for ER stress. J Am Soc Nephrol 2004; 15: 380-9.
65. Justo P, Lorz C, Sanz A, Egido J, Ortiz A. Intracellular mechanisms of cyclosporine A-induced tubular cell apoptosis. J Am Soc Nephrol 2003; 14: 3072-3080.
66. Ortiz A, Lorz C, Egido J. New kids in the block: the role of FasL and Fas in kidney damage. J Nephrol 1999; 12: 150-158.
67. Ortiz A, Lorz C, Egido J. The Fas ligand/ Fas system in renal injury. Nephrol Dial Transplant 1999; 14: 1831-1834.
68. Ortiz A, González-Cuadrado S, Bustos C, Alonso J, Gómez-Guerrero C, López- Armada MJ, González E, Plaza JJ, Egido J. Tumor necrosis factor and glomerular damage. J Nephrol 1995; 8: 27-34.
69. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 2000; 164: 2897-904.
70. Ortiz A, Lorz C, Catalán MP, Danoff TM, Yamasaki Y, Egido J, Neilson EG. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 2000; 57: 969-981.
71. Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferongamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin- 10. Transplantation 1995; 59: 565- 72.
72. Lorz C, Ortiz A, Justo P, González-Cuadrado S, Duque N, Gómez-Guerrero C, Egido J. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 2000; 11: 1266-77.
73. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffernburger DA, Yaffe MB. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005; 310: 1646-53.
74. Khwaja A, Tatton L. Resistance to the cytotoxic effects of tumor necrosis factor alpha can be overcome by inhibition of a FADD/caspase-dependent signalling pathway. J Biol Chem 1999; 274: 36817- 23.
75. Metz-Kurschel U, Kurschel E, Wagner K, Aulbert E, Graben N, Philipp T. Folate nephropathy occurring during cytotoxic chemotherapy with high-dose folinic acid and 5-fluorouracil. Ren Fail 1990; 12 (2): 93-7.
76. Ortega A, Ramila D, Ardura JA, Esteban V, Ruiz-Ortega M, Barat A, Gazapo R, Bosch RJ, Esbrit P. Role of parathyroid hormonerelated protein in tubulointerstitial apoptosis and fibrosis after folic Acid-induced nephrotoxicity. J Am Soc Nephrol 2006; 17: 1594-603.
77. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N, Schneider P, Scott ML, Hsu YM, Yagita H, Flavell RA, Miller JB, Burkly LC, Zheng TS. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 2006; 25: 5826-39.
78. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27: 242-50.